Non-Hodgkin Lymphomas

Chemotherapy: the backbone of lymphoma treatment

VJHemOnc is excited to present the latest developments in the role of chemotherapy across lymphomas

Pirtobrutinib receives accelerated FDA approval for the treatment of R/R mantle cell lymphoma

The Food and Drug Administration (FDA) granted accelerated approval to pirtobrutinib for the treatment of relapsed/refractory (R/R) mantle cell lymphoma…

ASH press briefing rundown: changing the status quo for blood cancers

VJHemOnc is thrilled to bring you the latest updates from the 64th American Society of Hematology (ASH) Annual Meeting and…

Biological therapy in NHL: treating with CAR-T versus BiTEs

VJHemOnc is pleased to bring you a feature exploring the latest developments in the treatment of NHL, with leading experts…

Highlights in lymphoid malignancies from EHA 2022

VJHemOnc is excited to bring you the latest research updates in lymphoid malignancies from the EHA 2022 Congress, which took…

Approval of axi-cel in second-line for R/R LBCL & label update

Axicabtagene ciloleucel (axi-cel) was approved by the FDA in October 2017 for patients with large B-cell lymphoma (LBCL) after two…

Highlights from the EBMT-EHA CAR T-cell 2022 Meeting

VJHemOnc is excited to bring you the latest research updates in CAR-T therapy from the EBMT-EHA 4th European CAR T-cell…

BTK inhibitors for B-cell malignancies: managing and improving class-driven adverse events

Bruton’s tyrosine kinase (BTK) inhibitors fulfill an increasingly important role in the treatment of patients with B-cell malignancies including chronic…

EHA 2021: key highlights in lymphoid malignancies

The 26th Congress of the European Hematology Association (EHA) 2021, which was held virtually from 9-17 of June, 2021, offered…

Highlights from the EBMT 2021 virtual meeting

VJHemOnc is excited to bring you highlights from the 47th Annual Meeting of the European Group for Blood and Marrow…

Non-covalent BTK inhibitor LOXO-305 shows promising results in advanced B-cell malignancies

Bruton’s tyrosine kinase (BTK) plays an essential role in the B-cell antigen receptor signaling pathway and is required for the…

Radioimmunotherapy agent improves progression-free survival of NHL patients in real-world setting

A study presented during the 2020 American Society of Clinical Oncology and Society for Immunotherapy of Cancer Clinical Immuno-Oncology Symposium,…

Microbiota diversity can predict mortality in patients undergoing allo-HSCT

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective and curative therapy for a large number of hematologic malignancies. Adverse…

iwNHL 2019 e-learning

View e-learning webcasts from iwNHL 2019 here!

The REAL classification of lymphoma

Twenty-five years ago, almost to the day, there was a paradigm shift in the classification of lymphoma.

iwNHL 2018
E-learning

VJHemOnc is pleased to bring e-learning webcasts from iwNHL 2018- explore updates in lymphoma!

features: Non-Hodgkin Lymphoma